Release Date: April 29, 2025
Expiration Date: April 29, 2026
Activity Overview
Although anti-VEGF therapies have advanced the management of nAMD and DME, limitations with their use – including the need for frequent injections – led to the development of newer anti-VEGF agents. In this program, a panel of expert faculty share a roundtable discussion to explore opportunities to educate patients on their treatment options, individualize anti-VEGF treatment intervals, and provide team-based care for these patients.
Target Audience
This online educational activity is directed toward retina specialists, ophthalmologists, and optometrists.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize disease and treatment burden that impact quality of life in nAMD
- Outline burden of disease and treatment in DME that impact quality of life
- Integrate real-world evidence into the development of individualized treatment plans for the management of nAMD
- Utilize evidence regarding advanced dosing strategies to create personalized management plans for patients with DME
Veeral Sheth, MD, MBA, FASRS, FACS
Director of Clinical Research
University Retina and Macula
Associates
Board Certified Ophthalmologist
and Retinal Surgeon
Clinical Assistant Professor
University of Illinois at Chicago
Chicago, IL
Disclosures: Grant/Research Support; 4D Molecular Therapeutics, AbbVie, Adverum Biotechnologies, Alimera Sciences, Ashvattha Therapeutics, Astellas Pharma, Aviceda Therapeutics, Chengdu Kanghong Pharmaceutical Group, Eluminex Biosciences, Eyebiotech, EyePoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, i-Lumen Scientific, Ionis Pharmaceuticals, IVERIC bio, Janssen Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Ocugen, Oculis, OcuTerra Therapeutics, OliX Pharmaceuticals, Opthea, Outlook Therapeutics, Oxular, Oxurion, Perfuse Therapeutics, RecensMedical, Regeneron Pharmaceuticals, Regenxbio, Rezolute, Roche, SalutarisMD, Sam Chun Dang, Santen Pharmaceutical, Smilebiotek, UNITY Biotechnology, Vanotech; Consultant: Alkeus Pharmaceuticals, Apellis Pharmaceuticals, Boehringer Ingelheim, EyePoint Pharmaceuticals, Genentech, IVERIC bio, Janssen Pharmaceuticals, Kriya Therapeutics, Novartis, Ocular Therapeutix, Oculis, Ocuphire Pharma, Ollin Biosciences, Opthea, Regeneron Pharmaceuticals, RevOpsis Therapeutics, UNITY Biotechnology, Vial.
Mark R. Barakat, MD, FASRS
Director of Clinical Research
Retina Macula Institute of Arizona
Medical Director, Spectra Eye Institute
Clinical Assistant Professor, University of Arizona College of Medicine - Phoenix
Phoenix, AZ
Disclosures: Grant/Research Support: Adverum Biotech, Annexon Biosciences, CalciMedica, Clearside Biomedical, Eyebiotech, EyePoint Pharma, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Kanghong/Vanotech, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Opthea, Oxular, Oxurion, Perfuse, Regenxbio, ReNeuron, Ribomic, Roche, Stealth Biotherapeutics, Unity Biotechnology; Speakers Bureau: Alcon, Apellis, Astellas, Bausch + Lomb, Genentech, Novartis, Regeneron; Consultant: AbbVie, Adverum Biotech, Alcon, Alimera, Allegro, Allergan, Annexon, Apellis, Arctic Vision, Astellas, Bausch + Lomb, BioCryst, Biogen, Boehringer Ingelheim, CalciMedica, Celltrion, Cencora, Clearside Biomedical, Coherus Biosciences, EyePoint Pharma, Genentech, Kodiak Sciences, Harrow, Janssen, Neurotech, Novartis, Ocular Therapeutix, Oculis, Opthea, Outlook Therapeutics, Palatin Technologies, Regeneron, Regenxbio, RevOpsis Therapeutics, Roche, Stealth Biotherapeutics; Other: NeuBase, Oxurion, RevOpsis Therapeutics.
Geeta Lalwani, MD
Physician and Founder
Rocky Mountain Retina Associates
Boulder, CO
Disclosures: Speakers Bureau: Genentech, Regeneron.
Xiao Yi Zhou, MD
Assistant Professor of
Ophthalmology and Visual
Science
Assistant Professor of Pathology
University of Chicago
Chicago, IL
Disclosures: Advisory Board: AbbVie.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here